Look for medical tech company TSO3 (TSO3 Stock Quote, Chart TSX:TOS) to become EBITDA-positive this year, says Echelon Wealth Partners analyst Douglas … [Read more...] about TSO3 Inc has a 181 per cent upside, says Echelon Wealth
Life Sciences
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
Profound Medical is a buy, says Mackie Research
After its preliminary quarterly revenue results, Mackie Research analyst André Uddin remains bullish on medical device company Profound Medical Corp … [Read more...] about Profound Medical is a buy, says Mackie Research
The Top 10 Canadian Biotech Stocks of 2018
The story of the Canadian Life Sciences sector mirrors that of the rest of the market: things were going great until the leaves began to fall. The … [Read more...] about The Top 10 Canadian Biotech Stocks of 2018
Correvio Pharma has an 89 per cent upside, Mackie Research says
After a volatile year in 2018, specialty pharma company Correvio Pharma (Correvio Pharma Stock Quote, Chart TSX, NASDAQ:CORV) still has plenty of room … [Read more...] about Correvio Pharma has an 89 per cent upside, Mackie Research says
The biotech sector is undervalued, John Zechner says
If you’re looking for a market sector that should do well in 2019, then biotechnology should be on your list, says John Zechner, who prefers Celgene … [Read more...] about The biotech sector is undervalued, John Zechner says
Investors can find defensive plays in biotech, Eden Rahim says
Like a number of sectors in the Canadian markets, biotech stocks had a rough ride over the latter half of 2018, as investors fled for seemingly safer … [Read more...] about Investors can find defensive plays in biotech, Eden Rahim says
Bellus Health has a 47 per cent upside, Mackie Research says
Bellus Health (Bellus Health Stock Quote, Chart TSX:BLU) is all cashed-up to start a Phase II trial of its chronic cough drug, one which analyst André … [Read more...] about Bellus Health has a 47 per cent upside, Mackie Research says
Acerus Pharmaceuticals has a 364 per cent upside, Mackie Research says
Following what he describes as positive results from a Phase 1 study, Mackie Research Capital analyst André Uddin is staying bullish on Acerus Pharma … [Read more...] about Acerus Pharmaceuticals has a 364 per cent upside, Mackie Research says
Echelon Wealth Partners turns bullish on beaten down ProMetic Life Sciences
A new development for ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart TSX:PLI) has Echelon Wealth Partners analyst Douglas Loe … [Read more...] about Echelon Wealth Partners turns bullish on beaten down ProMetic Life Sciences
Knight Therapeutics CEO Jonathan Goodman is a genius, this investor says
Specialty pharma company Knight Therapeutics (Knight Therapeutics Stock Quote, Chart TSX:GUD) has been trading sideways for over a year now, but … [Read more...] about Knight Therapeutics CEO Jonathan Goodman is a genius, this investor says